iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
81 hedge funds and large institutions have $1.03B invested in iTeos Therapeutics in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 35 increasing their positions, 13 reducing their positions, and 9 closing their positions.
169% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 13
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
14% more funds holding
Funds holding: 71 → 81 (+10)
13% more capital invested
Capital invested by funds: $907M → $1.03B (+$121M)
8.97% more ownership
Funds ownership: 76.75% → 85.72% (+9%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$61M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$33.6M |
| 3 |
CAC
Cowen and Company
New York
|
+$21.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$18.6M |
| 5 |
BlackRock
New York
|
+$16.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$29.4M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$15.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$10.3M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$5.41M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$3.38M |
ITOS Hedge Fund Activity: Q1 2021 in Review
81 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q1 2021, worth a combined $1.03B — up 13% from $907M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ITOS positions and 9 closed out — a net gain of 10 holders — while 35 added to existing stakes and 13 trimmed.
The largest buyer was RTW Investments, adding an estimated $61M. The largest seller was Janus Henderson Group, cutting an estimated $29.4M.
- 81 institutional investors held iTeos Therapeutics (ITOS) as of Q1 2021, up from 71 in Q4 2020.
- Funds reported $1.03B of iTeos Therapeutics stock for Q1 2021, up 13% quarter-over-quarter.
- 19 funds opened new iTeos Therapeutics positions in Q1 2021 and 9 closed out, a net change of +10 holders.
- The largest iTeos Therapeutics buyer in Q1 2021 was RTW Investments, an estimated $61M added.
- The largest iTeos Therapeutics seller in Q1 2021 was Janus Henderson Group, an estimated $29.4M sold.
Based on aggregated 13F filings for Q1 2021.